What is the therapeutic effect of mivamutide injection?

Mifamurtide injection (Mifamurtide) is an immunomodulator, mainly used to treat osteosarcoma, especially for postoperative adjuvant treatment of patients with high-grade, resectable, non-metastatic osteosarcoma. The drug's active ingredient, mifamotide, exerts anti-tumor effects by activating macrophages and monocytes in the immune system. The specific mechanism of action of mivamutin has not yet been fully revealed, but research shows that it helps the body eliminate residual tumor cells by enhancing the function of immune cells, thereby reducing the risk of cancer recurrence.

Osteosarcoma is an extremely aggressive cancer that primarily affects children and young adults, and is particularly common in long bones such as the thighbone and tibia. Since osteosarcoma usually has no obvious symptoms in the early stages, many patients are already in advanced stages when diagnosed, and the tumors are often accompanied by metastasis. Although surgical resection and chemotherapy are common treatments for osteosarcoma, even patients who have undergone surgical resection still face a high risk of recurrence. Therefore, postoperative adjuvant treatment is particularly important. As a new type of immunotherapy, mivamutide provides a new treatment option for these patients.

In a clinical study involving678 patients with high-grade non-metastatic osteosarcoma aged between 1 and 31 years old, the effect of mivamutide was initially verified. Patients in this study were treated with a combination of anti-cancer drugs after surgery to remove the tumors. Half of the patients received mivamutin injections in addition to their usual treatment. The primary endpoint of the study was to compare disease-free survival (DFS) between patients who received mivamutide and those who did not.

The results of this study show that mivamutide significantly improved the patients' disease-free survival rate. Specifically, 68% of patients who received mivamutide remained disease-free after treatment, while only 61% of patients who did not receive the drug maintained disease-free survival. In addition, patients treated with mivamutide also showed certain advantages in overall survival (OS), with a 28% reduction in the risk of death.

These research results show that miavamutin can not only effectively reduce the risk of recurrence in patients with osteosarcoma, but also significantly improve the survival rate of patients. Compared with traditional anti-cancer drugs such as chemotherapy and radiotherapy, the mechanism of action of mivamutin is more focused on enhancing the patient's anti-tumor ability through activation of the immune system, rather than relying solely on chemical drugs to directly kill cancer cells. This immune-enhancing effect makes mivamutide an important part of postoperative treatment for patients with osteosarcoma, especially when it reduces the residual tumor cells and can effectively prevent disease recurrence.

The therapeutic effect of mivamutide is also reflected in improving the quality of life of patients. Because mivamutin has a mild immunomodulatory effect, it has relatively fewer side effects than traditional chemotherapy drugs. Patients usually do not experience obvious chemotherapy-related side effects, such as severe nausea, vomiting or immunosuppression, during treatment with mivamutide, which allows patients to maintain a good physical condition during treatment and further improves the acceptability of treatment.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact